AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims:

1. (Currently amended) A process for analysing the saccharide content of a composition, wherein:

   (a) the composition comprises a capsular saccharide from serogroup C of *Neisseria meningitidis* and one or both of: (i) a capsular saccharide from serogroup W135 of *Neisseria meningitidis*; and/or (ii) a capsular saccharide from serogroup Y of *Neisseria meningitidis*;

   (b) the process comprises a step of analysing the sialic acid content of the composition, and: (i) if the composition includes a serogroup W135 saccharide, a step of analysing the galactose content of the composition; (ii) if the composition includes a serogroup Y saccharide, a step of analysing the glucose content of the composition;

   (c) if the composition includes a serogroup W135 saccharide, the content of serogroup W135 saccharide in the composition is determined according to the results of the galactose analysis from step (b);

   (d) if the composition includes a serogroup Y saccharide, the content of serogroup Y saccharide in the composition is determined according to the results of the glucose analysis from step (b); and

   (e) the content of serogroup C saccharide in the composition is accurately determined by ~~comparing the results of the sialic acid analysis with~~: (i) if the composition includes a serogroup W135 saccharide but not a serogroup Y saccharide, ~~the results of~~ subtracting the galactose ~~analysis~~ content of the composition from step (b) from the sialic acid content of the composition from step (b), to determine the content of serogroup C saccharide in the composition; (ii) if the composition includes a serogroup Y saccharide but not a serogroup W135 saccharide, ~~the results of~~ subtracting the glucose ~~analysis~~ content of the composition from step (b) from the sialic acid content of the composition from step (b), to determine the content of serogroup C saccharide in the composition; or

(iii) if the composition includes both a serogroup W135 saccharide and a serogroup Y saccharide, ~~the combined results of~~ subtracting the combined glucose and galactose ~~analyses~~ content of the composition from step (b) from the sialic acid content of the composition from step (b), to determine the content of serogroup C saccharide in the composition.

2. (Original) The process of claim 1, wherein the composition comprises capsular saccharide from all three of serogroups C, W135 and Y of *Neisseria meningitides*.

3. (Original) The process of claim 2, wherein the composition comprises one or more further capsular saccharide(s).

4. (Original) The process of claim 3, wherein the one or more further capsular saccharide(s) is/are selected from the group consisting of: a capsular saccharide from serogroup A of *N. meningitidis*; and a capsular saccharide from *Haemophilus influenzae* b.

5. (Previously presented) The process of claim 1, including a step of treating the composition in order to depolymerise the capsular saccharides to give their constituent monosaccharides.

6. (Previously presented) The process of claim 1, wherein sialic acid content, glucose content and/or galactose content are measured by high performance anion exchange chromatography, optionally with pulsed amperometric detection.

7. (Previously presented) The process of claim 1, wherein the process also includes step(s) in which one of more of the following components or properties is/are analysed: osmolality, pH, degree of polymerisation for individual saccharides or conjugates, protein content, aluminium content, detergent content, and preservative content.

8. (Previously presented) The process of claim 1, wherein the capsular saccharides are derived from a saccharide-protein conjugate.

9. (Original) The process of claim 8, wherein the protein in the conjugate is a bacterial toxin or toxoid.

10. (Original) The process of claim 9, wherein the toxin or toxoid is selected from the group consisting of: diphtheria toxoid; tetanus toxoid; the CRM197 diphtheria toxin derivative; and protein D from *H. influenzae*.

11. (Original) A process for analysing a composition, wherein:

    (a) the composition comprises a conjugate of a capsular saccharide from serogroup C of *Neisseria meningitidis* and one or both of: (i) a conjugate of a capsular saccharide from serogroup W135 of *Neisseria meningitidis*; and/or (ii) a conjugate of a capsular saccharide from serogroup Y of *Neisseria meningitidis*;
    (b) the composition may comprise the capsular saccharides in unconjugated form;
    (c) the content of any unconjugated capsular saccharides is determined by the process of any one of claims 1 to 7;
    (d) the content of conjugated capsular saccharides is determined by the process of any one of claims 1 to 7; and, optionally,
    (e) the ratio of conjugated:unconjugated saccharide in the composition is calculated for one or more of the capsular saccharides.

12. (Canceled).

13. (Previously presented) A method for releasing a vaccine for use by physicians, comprising the steps of: (a) manufacturing a vaccine containing a conjugate of a capsular saccharide from serogroup C of *Neisseria meningitidis* and one or both of: (i) a conjugate of a capsular saccharide from serogroup W135 of *Neisseria meningitidis*; and/or (ii) a conjugate of a capsular saccharide from serogroup Y of *Neisseria meningitidis*; (b) analysing the amount of conjugated and/or unconjugated saccharide in the vaccine for each of said capsular saccharides, according to the process of claim 1; and, if the results from step (b) indicate a saccharide content acceptable for clinical use, (c) releasing the vaccine for use by physicians.

14. (Withdrawn) Two batches of a vaccine, wherein:

(a) each of the batches of vaccine comprises: a conjugate of a capsular saccharide from serogroup C of *Neisseria meningitidis* and one or both of: (i) a conjugate of a capsular saccharide from serogroup W135 of *Neisseria meningitidis*; and/or (ii) a conjugate of a capsular saccharide from serogroup Y of *Neisseria meningitidis*;

(b) the concentration of conjugated serogroup C saccharide in the first batch is C_1;

(c) the concentration of conjugated serogroup C saccharide in the second batch is C_2;

if applicable, (d) the concentration of conjugated serogroup W135 saccharide in the first batch is W_1;

if applicable, (e) the concentration of conjugated serogroup W135 saccharide in the second batch is W_2;

if applicable, (f) the concentration of conjugated serogroup Y saccharide in the first batch is Y_1;

if applicable, (g) the concentration of conjugated serogroup Y saccharide in the second batch is Y_2;

and wherein (h) the ratios C_1/C_2, W_1/W_2 and Y_1/Y_2 are each between 0.90 and 1.10.

15. (Withdrawn) The batches of claim 14, wherein: (i) the concentration of unconjugated serogroup C saccharide in the first batch is C_3; (j) the concentration of unconjugated serogroup C saccharide in the second batch is C_4; if applicable, (k) the concentration of unconjugated serogroup W135 saccharide in the first batch is W_3; if applicable, (l) the concentration of unconjugated serogroup W135 saccharide in the second batch is W_4; if applicable, (m) the concentration of unconjugated serogroup Y saccharide in the first batch is Y_3; if applicable, (n) the concentration of unconjugated serogroup Y saccharide in the second batch is Y_4; (o) the ratios C_3/C_4, W_3/W_4 and Y_3/Y_4 are each between 0.90 and 1.10, and preferably are each between 0.95 and 1.05.

16. (Withdrawn) The batches of claim 15, wherein (p) the ratios C_3/C_1, C_4/C_2, W_3/W_1, W_4/W_2, Y_3/Y_1, and Y_4/Y_2 are each less than 0.20.

17. (Currently amended) A computer apparatus, comprising a non-transitory computer-readable storage medium storing computer-executable instructions for performing the process steps of any one of claims 1 to [[12]] 11.

18. (Currently amended) A non-transitory computer-readable storage medium storing computer-executable instructions for analysing the saccharide content of a composition as defined in claim 1, comprising computer-executable instructions for: (a) receiving data on the sialic acid content, and on the glucose and/or galactose content, of a sample; and (b) calculating from those data the content of capsular saccharide from serogroup C and from serogroup W135 and/or Y.

19. (Previously presented) The process of claim 2, including a step of treating the composition in order to depolymerise the capsular saccharides to give their constituent monosaccharides.

20. (Previously presented) The process of claim 3, including a step of treating the composition in order to depolymerise the capsular saccharides to give their constituent monosaccharides.

21. (Previously presented) The process of claim 4, including a step of treating the composition in order to depolymerise the capsular saccharides to give their constituent monosaccharides.